Cargando…

Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

SIMPLE SUMMARY: Non-surgical management of hepatocellular carcinoma (HCC) is used for selected patients. Of these management options, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) are the two main locoregional treatment options. There was no difference in OS among patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Lawson, Alexander, Kamarajah, Sivesh K., Parente, Alessandro, Pufal, Kamil, Sundareyan, Ramanivas, Pawlik, Timothy M., Ma, Yuk Ting, Shah, Tahir, Kharkhanis, Salil, Dasari, Bobby V. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296639/
https://www.ncbi.nlm.nih.gov/pubmed/37370776
http://dx.doi.org/10.3390/cancers15123166
_version_ 1785063697142513664
author Lawson, Alexander
Kamarajah, Sivesh K.
Parente, Alessandro
Pufal, Kamil
Sundareyan, Ramanivas
Pawlik, Timothy M.
Ma, Yuk Ting
Shah, Tahir
Kharkhanis, Salil
Dasari, Bobby V. M.
author_facet Lawson, Alexander
Kamarajah, Sivesh K.
Parente, Alessandro
Pufal, Kamil
Sundareyan, Ramanivas
Pawlik, Timothy M.
Ma, Yuk Ting
Shah, Tahir
Kharkhanis, Salil
Dasari, Bobby V. M.
author_sort Lawson, Alexander
collection PubMed
description SIMPLE SUMMARY: Non-surgical management of hepatocellular carcinoma (HCC) is used for selected patients. Of these management options, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) are the two main locoregional treatment options. There was no difference in OS among patients treated with TACE/TAE, single versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has a comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs, which are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future. ABSTRACT: Although hepatocellular carcinoma is increasingly common, debate exists surrounding the management of patients with unresectable disease comparing transarterial embolisation (TAE) or transarterial chemoembolisation (TACE). This study aimed to compare the outcomes of patients receiving TAE and TACE. A systematic review was performed using PubMed, Medline, Embase, and Cochrane databases to identify randomised controlled trials (RCTs) until August 2021. The primary outcome was overall survival (OS) and the secondary outcomes were progression-free survival (PFS) and adverse events. Five studies with 609 patients were included in the analysis. There was no statistically significant difference in the OS (p = 0.36) and PFS (p = 0.81). There was no difference in OS among patients treated with a single TACE/TAE versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future.
format Online
Article
Text
id pubmed-10296639
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102966392023-06-28 Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Lawson, Alexander Kamarajah, Sivesh K. Parente, Alessandro Pufal, Kamil Sundareyan, Ramanivas Pawlik, Timothy M. Ma, Yuk Ting Shah, Tahir Kharkhanis, Salil Dasari, Bobby V. M. Cancers (Basel) Systematic Review SIMPLE SUMMARY: Non-surgical management of hepatocellular carcinoma (HCC) is used for selected patients. Of these management options, transarterial embolisation (TAE) and transarterial chemoembolisation (TACE) are the two main locoregional treatment options. There was no difference in OS among patients treated with TACE/TAE, single versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has a comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs, which are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future. ABSTRACT: Although hepatocellular carcinoma is increasingly common, debate exists surrounding the management of patients with unresectable disease comparing transarterial embolisation (TAE) or transarterial chemoembolisation (TACE). This study aimed to compare the outcomes of patients receiving TAE and TACE. A systematic review was performed using PubMed, Medline, Embase, and Cochrane databases to identify randomised controlled trials (RCTs) until August 2021. The primary outcome was overall survival (OS) and the secondary outcomes were progression-free survival (PFS) and adverse events. Five studies with 609 patients were included in the analysis. There was no statistically significant difference in the OS (p = 0.36) and PFS (p = 0.81). There was no difference in OS among patients treated with a single TACE/TAE versus repeat treatments. Post-procedural adverse effects were higher in the TACE group but were not statistically significant. TACE has comparable long-term survival and complications profile to TAE for patients with HCC. However, the low-to-moderate quality of current RCTs warrants high-quality RCTs are necessary to provide enough evidence to give a definitive answer and inform treatment plans for the future. MDPI 2023-06-13 /pmc/articles/PMC10296639/ /pubmed/37370776 http://dx.doi.org/10.3390/cancers15123166 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Lawson, Alexander
Kamarajah, Sivesh K.
Parente, Alessandro
Pufal, Kamil
Sundareyan, Ramanivas
Pawlik, Timothy M.
Ma, Yuk Ting
Shah, Tahir
Kharkhanis, Salil
Dasari, Bobby V. M.
Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
title Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
title_full Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
title_fullStr Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
title_full_unstemmed Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
title_short Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
title_sort outcomes of transarterial embolisation (tae) vs. transarterial chemoembolisation (tace) for hepatocellular carcinoma: a systematic review and meta-analysis
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296639/
https://www.ncbi.nlm.nih.gov/pubmed/37370776
http://dx.doi.org/10.3390/cancers15123166
work_keys_str_mv AT lawsonalexander outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT kamarajahsiveshk outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT parentealessandro outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT pufalkamil outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT sundareyanramanivas outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT pawliktimothym outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT mayukting outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT shahtahir outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT kharkhanissalil outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis
AT dasaribobbyvm outcomesoftransarterialembolisationtaevstransarterialchemoembolisationtaceforhepatocellularcarcinomaasystematicreviewandmetaanalysis